Jay Peterson

John (Jay) Peterson is a senior biopharmaceutical operations executive with more than 20 years of experience leading large scale biologics manufacturing, commercialization, and technical operations. He has built a career focused on scaling complex GMP manufacturing environments, advancing monoclonal antibody platforms, and delivering reliable clinical and commercial supply in highly regulated settings. His leadership spans end to end biologics development from early stage programs through Phase III and commercial production, with a consistent focus on execution, quality, and operational discipline. He has led major operational transformations across biologics manufacturing sites, including the build out and expansion of large scale GMP facilities and the establishment of integrated technical services and manufacturing science functions. His work has included overseeing capital expansion projects, strengthening technology transfer capabilities, and aligning engineering, quality, and manufacturing teams to improve speed to market and operational stability. He is known for bringing structure to complex environments and improving performance across production systems through practical, data informed decision making. In senior leadership roles, John has directed site level operations and cross functional teams responsible for bioprocessing, manufacturing operations, and lifecycle management of biologics products. He has managed multimillion dollar budgets, built high performing teams, and ensured consistent execution across upstream, downstream, and fill finish operations. His experience includes strengthening cGMP compliance, improving supply reliability, and leading organizations through acquisition integration and operational scale up. John has deep expertise in monoclonal antibody manufacturing and biologics process development, with a strong track record of enabling successful tech transfer from research and development into commercial production. He has worked closely with regulatory frameworks including FDA and EU requirements and has consistently ensured inspection readiness and quality system maturity. His approach combines technical depth with operational leadership, allowing him to bridge science, engineering, and business priorities effectively. He is recognized for building strong teams and fostering a culture of accountability, continuous improvement, and performance excellence. Throughout his career he has partnered with executive stakeholders to deliver enterprise value through capacity expansion, process optimization, and commercialization readiness. He holds a Bachelor of Science in Chemistry and Biology and continues to focus on advancing biologics manufacturing capabilities that support innovation and patient access.